MicroRNA-296-5p Expression in COVID-19 Patients and its Relationship with Inflammatory Cytokines
-
Sepideh Barzin Tond
,
Sahar Yarahmadi
,
Reza Fadaei
,
Navid Farahmandian
,
Mohammadjavad Sotoudeheian
,
Rahim Rostami
,
Nasim Khajavirad
,
Abbas Tafakhori
,
Minoosh Shabani
,
Ali Riazi
,
Soudabeh Fallah
,
Saeed Karima *,
Abstract
Objects: Coronavirus, a positive-sense, single-stranded RNA virus with ~30 kb, can infect various host species. Cytokine storm, caused by the activation of some pro-inflammatory genes in the second phase of COVID-19 as an infectious and contagious disease, is accompanied by severe acute respiratory disorder. Based on the evidence, microRNAs (miR) and cytokine levels can play a critical role in host cell antiviral defense mechanisms. The present study investigates the pattern changes of IP-10 and miR-296-5p genes expression as well as their relationship with some inflammatory cytokines and biochemical variables in COVID-19 patients.
Methods: Present retrospective single-center study was conducted on 30 COVID-19 patients and 30 controls. Peripheral blood mononuclear cell (PBMC) miR-296-5p and IP-10 gene expression were evaluated using real-time PCR. IL-6, TNF-α, and CRP serum levels were measured by utilizing ELISA.
Results: Higher miR-296-5p and IP-10 genes expression in COVID-19 patients compared to controls (P=0.001) were revealed as a result of this study. Moreover, IP-10, IL-6, and TNF-α levels were significantly higher (P<0.01) in COVID-19 patients than in controls. Furthermore, results showed positive correlations between miR-296-5p expression and serum levels of IL-6, CRP, and TNF-α in patients with COVID-19. ROC curve analysis of miR-296-5p in COVID-19 patients showed an [area under curve=0.830, 95% CI (0.658-0.815), P<0.001] with an optimal cut-off point of 0.32965.
Conclusions: Our results suggest regulatory role of miR-296-5p in COVID-19 for cytokine secretion. The results indicate that PBMC expression of miR-296-5p and IP-10 genes might be convenient novel biomarkers for prognosis of COVID-19.
2. Yang, Z.-Y., Y. Huang, L. Ganesh, K. Leung, W.-P. Kong, O. Schwartz, et al., pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. Journal of virology, 2004. 78(11): p. 5642-5650.
3. Hall, K.S., G. Samari, S. Garbers, S.E. Casey, D.D. Diallo, M. Orcutt, et al., Centring sexual and reproductive health and justice in the global COVID-19 response. The lancet, 2020. 395(10231): p. 1175-1177.
4. Guan, W.-j., Z.-y. Ni, Y. Hu, W.-h. Liang, C.-q. Ou, J.-x. He, et al., Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 2020. 382(18): p. 1708-1720.
5. Mehta, P., D.F. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, and J.J. Manson, COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet, 2020. 395(10229): p. 1033-1034.
6. Qin, C., L. Zhou, Z. Hu, S. Zhang, S. Yang, Y. Tao, et al., Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases, 2020. 71(15): p. 762-768.
7. Del Valle, D.M., S. Kim-Schulze, H.-H. Huang, N.D. Beckmann, S. Nirenberg, B. Wang, et al., An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature medicine, 2020. 26(10): p. 1636-1643.
8. Dufour, J.H., M. Dziejman, M.T. Liu, J.H. Leung, T.E. Lane, and A.D. Luster, IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. The Journal of Immunology, 2002. 168(7): p. 3195-3204.
9. Ostovar, T., G. Goodarzi, and S.S. Tehrani, Modulation of cancer progression by circRNA/NF-kB axis. Acta Biochimica Iranica, 2024.
10. Lev, S., T. Gottesman, G. Sahaf Levin, D. Lederfein, E. Berkov, D. Diker, et al., Observational cohort study of IP-10’s potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19. Plos one, 2021. 16(1): p. e0245296.
11. Kazemi Fard, T., S. Tavakoli, R. Ahmadi, N. Moradi, R. Fadaei, A. Mohammadi, et al., Evaluation of IP10 and miRNA 296-a expression levels in peripheral blood mononuclear cell of coronary artery disease patients and controls. DNA and Cell Biology, 2020. 39(9): p. 1678-1684.
12. Fadaei, R., E. Parvaz, S. Emamgholipour, N. Moradi, A. Vatannejad, M. Najafi, et al., The mRNA expression and circulating levels of visfatin and their correlation with coronary artery disease severity and 25-hydroxyvitamin D. Hormone and metabolic research, 2016. 48(04): p. 269-274.
13. Tay, M.Z., C.M. Poh, L. Rénia, P.A. MacAry, and L.F. Ng, The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology, 2020. 20(6): p. 363-374.
14. Cummings, M.J., M.R. Baldwin, D. Abrams, S.D. Jacobson, B.J. Meyer, E.M. Balough, et al., Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The lancet, 2020. 395(10239): p. 1763-1770.
15. Huang, C., Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 2020. 395(10223): p. 497-506.
16. Chen, Y., J. Wang, C. Liu, L. Su, D. Zhang, J. Fan, et al., IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Molecular Medicine, 2020. 26: p. 1-12.
17. Chow, J.T.-S. and L. Salmena, Prediction and analysis of SARS-CoV-2-targeting MicroRNA in human lung epithelium. Genes, 2020. 11(9): p. 1002.
| Files | ||
| Issue | Vol 2 No 1 (2024) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/abi.v2i1.16274 | |
| Keywords | ||
| : SARS-COV-2 COVID-19 miRNA Inflammation Cytokine IP-10 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
